Researchers from the University of Pittsburgh studied 68 men with prostate cancer: 41 taking androgen deprivation therapy and 27 not receiving the treatment. All underwent periodontal examinations before and after treatment to establish the existence and severity of gum disease, inflammation and infection of the gums, connective tissue and bones supporting and surrounding the teeth.
The study found that 81 percent of the participants receiving androgen deprivation therapy showed signs of gum disease, while only 3.8 percent of the men not receiving the therapy had gum disease. Even when controlling for race, smoking history or previous periodontal treatment, the men on the therapy were more than three times more likely to have gum disease than men not on the therapy, researchers said.
They noted that bone mineral density—the traditional method of determining bone loss from osteoporosis—was not significantly different between the two groups of men. Erosion of the bones supporting the teeth may be one explanation for the increased incidence of gum disease, but the bone mineral density levels were the same in the two groups. The researchers concluded that more studies are needed to confirm their results and possibly find methods to prevention gum disease in men undergoing the prostate treatment.
Results of the study were published in the March issue of the Journal of Urology.
Copyright 2007 iVillage Total Health.